Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Medical Device

IceCure Medical Secures Chinese Patent for Cryogenic System Connector

Fineline Cube Mar 18, 2025

Israel-based IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving patent authorization from the China National Intellectual...

Company

FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development

Fineline Cube Mar 18, 2025

US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...

Company Deals

Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio

Fineline Cube Mar 18, 2025

Japan-based Taiho Pharmaceutical Co., Ltd. announced plans to fully acquire Araris Biotech AG, a Swiss...

Company Drug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Fineline Cube Mar 18, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational...

Company Medical Device

Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA

Fineline Cube Mar 18, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced receiving market approval from the National Medical Products...

Company Deals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Fineline Cube Mar 18, 2025

Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...

Company Drug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Fineline Cube Mar 18, 2025

Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Fineline Cube Mar 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...

Company Drug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

Fineline Cube Mar 18, 2025

China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...

Company Deals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

Fineline Cube Mar 17, 2025

On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....

Company Deals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies

Fineline Cube Mar 17, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...

Company Drug

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

Fineline Cube Mar 17, 2025

US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...

Company Drug

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment

Fineline Cube Mar 17, 2025

Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...

Company Medical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Fineline Cube Mar 17, 2025

China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...

Company Deals Drug

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Fineline Cube Mar 17, 2025

Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...

Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

Fineline Cube Mar 17, 2025

California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...

Company Drug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 17, 2025

US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...

Company Deals

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline

Fineline Cube Mar 17, 2025

Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...

Company Drug

Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection

Fineline Cube Mar 17, 2025

Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET...

Company Drug

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study

Fineline Cube Mar 17, 2025

Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...

Posts pagination

1 … 198 199 200 … 669

Recent updates

  • Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.